Sometimes, proteins your body makes can cause or contribute to disease. These proteins can be either be faulty, or healthy. RNAi therapeutics are a type of medicine, pioneered by Alnylam, that treats disease by targeting and disabling specific mRNA (messenger RNA) which tell your body how to make these unwanted proteins. #ScienceCurious to learn more about the science of #RNAi? Click here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #science
Alnylam Pharmaceuticals
バイオテクノロジー研究
Cambridge、Massachusetts197,135人のフォロワー
Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.
概要
ALNYLAM IS LEADING THE RNAi REVOLUTION™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,500 people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-23), Science Magazine (2018-23), Fast Company (Best Workplaces for Innovators 2020-23) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, 31 20 369 7861
- ウェブサイト
-
http://www.alnylam.com
Alnylam Pharmaceuticalsの外部リンク
- 業種
- バイオテクノロジー研究
- 会社規模
- 社員 1,001 - 5,000名
- 本社
- Cambridge、Massachusetts
- 種類
- 上場企業
- 創立
- 2002
- 専門分野
- Biotech、Pharmaceuticals、Biopharma、Drug Development、Rare Diseases、RNAi
場所
Alnylam Pharmaceuticalsの社員
アップデート
-
With warmer months and family gatherings ahead, summer is the perfect time to discuss health with your loved ones. Hear from Renee and her father, Julio, who uncovered a health mystery that goes back generations at a family reunion. Learn more about #hATTR #amyloidosis here: https://bit.ly/3QPohJd #hATTRoadTrip
-
Proteins are the "workers" in the biochemistry of life and are critical to almost everything your body does, but sometimes, they can also cause or contribute to disease. RNAi therapeutics, which were pioneered by Alnylam, work by preventing the production of specific unwanted proteins. #ScienceCurious to learn more about the science of #RNAi? Read more here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #science
-
What a week last week! Every Alnylam achievement, RNAi therapeutics advancement and milestone (such as our HELIOS-B topline data, which we were celebrating), is made possible because of the passion, innovation and perseverance of our 2,000 employees who are unwavering in their dedication to our mission. Together, we are leading the #RNAiRevolution. #RNAiTherapeutics #RNAi #siRNA #CompanyCulture
-
-
-
-
-
11
-
-
Healthcare Professionals: #hATTR #amyloidosis is a progressive and often fatal disease that affects multiple organs and tissues, resulting in a highly varied symptom presentation. Learn more about some different patient types that could be in your practice. https://bit.ly/3NuMgL9
-
RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #RNA
-
An Alnylam team took steps to raise funds for the Huntington's Disease Society of America —literally. 👣 With kids in tow, colleagues participated in Team Hope Walk last weekend on Castle Island in Boston. We’re raising awareness about this devastating #RareDisease. Learn more about #HuntingtonsDisease: https://hdsa.org/
-
-
Alnylam Pharmaceuticalsさんが再投稿しました
It gives me immense PRIDE to attend events like today’s ‘Show your PRIDE’ lunch at Alnylam in Zug. At @AlnylamPharmaceuticals, our PRIDE theme is Diverse Equal Proud. It’s about recognizing the diversity of people within the LGBTQ community and the fact that everyone deserves to be proud of who they are and treated with equal respect and dignity, regardless of gender, ethnicity or background. As an Executive Sponsor of our employee network SAGA – the Sexuality And Gender Alliance – it’s wonderful to see the company come together to celebrate PRIDE Month, showing our support and allyship. Throughout June, Alnylam has been proudly decorated with rainbows – from rainbow Zoom backgrounds to rainbow lanyards, and a variety of colorful PRIDE-themed events have been held across our offices globally to celebrate acceptance and diversity. I’m very proud to be an ally and to work at a company that lives and breathes its commitment to inclusivity as strongly as Alnylam does. It is so important that everyone feels able to bring their authentic self to work, and to be accepted and respected for who they truly are. I have such huge admiration for everyone who has trailblazed the path to improving LGBTQ acceptance across the world, and to all those I know – at Alnylam and beyond – who have been on their own personal LGBTQ journeys. But I also know so much progress is still to be made, and each and every one of us needs to play a part in supporting this. #PRIDEmonth #PRIDE2024 #alnylamproud
-
-
Dr. Fontana, an investigator on the HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis with cardiomyopathy, shares her thoughts on the positive topline results. Full results will be presented at an upcoming medical meeting. #RNAiTherapeutics
-
-
Our CEO Dr. Yvonne Greenstreet shares her thoughts on the positive Phase 3 topline results from our HELIOS-B study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis w/ cardiomyopathy. Read the press release: https://bit.ly/3VwvRtY #RNAitherapeutics #siRNA